Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)

Igor Stukalin; J. Connor Wells; Anna Fraccon; Felice Pasini; Camillo Porta; Aly Khan A. Lalani; Sandy Srinivas; I. Alex Bowman; James Brugarolas; Jae Lyun Lee; Frede Donskov; Benoit Beuselinck; Aristotelis Bamias; Brian I. Rini; Hao Wen Sim; Neeraj Agarwal; Sun Young Rha; Ravindran Kanesvaran; Toni K. Choueiri; Daniel Y.C. Heng

doi:10.3233/KCA-170020

Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)

Igor Stukalin, J. Connor Wells, Anna Fraccon, Felice Pasini, Camillo Porta, Aly Khan A. Lalani, Sandy Srinivas, I. Alex Bowman, James Brugarolas, Jae Lyun Lee, Frede Donskov, Benoit Beuselinck, Aristotelis Bamias, Brian I. Rini, Hao Wen Sim, Neeraj Agarwal, Sun Young Rha, Ravindran Kanesvaran, Toni K. Choueiri, Daniel Y.C. Heng

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: Fourth-line therapy (4LT) in the treatment of metastatic renal cell carcinoma (mRCC) varies significantly due to the lack of data and recommendations to guide treatment decisions. Objective: To evaluate the use and efficacy of 4LT in mRCC patients. Methods: The International mRCC Database Consortium (IMDC) dataset was used to identify patients with mRCC treated with 4LT. This is a multicenter, retrospective cohort study. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier curves. Patients were evaluated for overall response. The six prognostic variables included in the IMDC prognostic model were used to stratify patients into favorable-, intermediate- and poor-risk groups. Exploratory analyses were performed examining the elderly (>70 years old) and non-clear cell RCC subgroups. Proportional hazards regression modelling was performed adjusting these covariates by IMDC criteria measured at initiation of 4th line therapy. Results: 7498 patients were treated with first line targeted therapy and out of these 594 (7.9%) received 4LT. Everolimus was the most frequently used 4LT (16.8%). Sorafenib, axitinib, pazopanib, sunitinib and clinical trial drugs were also used in >10% of patients. The OS of patients on any 4LT was 12.8 months, with a PFS of 4.4 months. The overall response rate (ORR) was 13.7%. Favorable-risk patients using IMDC criteria (5%) displayed an OS of 23.1 months, intermediate-risk patients (66%) had an OS of 13.8 months and poor-risk patients (29%) had an OS of 7.8 (p < 0.0001) months. Age >70 years and non-clear cell histology did not impact OS. Our study is limited by its retrospective design. Conclusions: 4LT use appears to have activity in mRCC patients. The IMDC continues to be of prognostic value in the fourth-line setting for OS. This study helps to set a benchmark for response rate and survival for which clinical trials can plan sample size calculations and aim to improve upon.

Original language	English (US)
Pages (from-to)	31-36
Number of pages	6
Journal	Kidney Cancer
Volume	2
Issue number	1
DOIs	https://doi.org/10.3233/KCA-170020
State	Published - 2018

Keywords

Checkpoint inhibitors
Fourth line therapy
Metastatic renal cell carcinoma
Targeted therapy

ASJC Scopus subject areas

Nephrology
Oncology

Access to Document

10.3233/KCA-170020

Cite this

Stukalin, I., Connor Wells, J., Fraccon, A., Pasini, F., Porta, C., Lalani, A. K. A., Srinivas, S., Alex Bowman, I., Brugarolas, J., Lee, J. L., Donskov, F., Beuselinck, B., Bamias, A., Rini, B. I., Sim, H. W., Agarwal, N., Rha, S. Y., Kanesvaran, R., Choueiri, T. K., & Heng, D. Y. C. (2018). Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC). Kidney Cancer, 2(1), 31-36. https://doi.org/10.3233/KCA-170020

Stukalin, I, Connor Wells, J, Fraccon, A, Pasini, F, Porta, C, Lalani, AKA, Srinivas, S, Alex Bowman, I, Brugarolas, J, Lee, JL, Donskov, F, Beuselinck, B, Bamias, A, Rini, BI, Sim, HW, Agarwal, N, Rha, SY, Kanesvaran, R, Choueiri, TK & Heng, DYC 2018, 'Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)', Kidney Cancer, vol. 2, no. 1, pp. 31-36. https://doi.org/10.3233/KCA-170020

@article{9061257ab2d3431ab42c9fe7c85f71c9,

title = "Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)",

abstract = "Background: Fourth-line therapy (4LT) in the treatment of metastatic renal cell carcinoma (mRCC) varies significantly due to the lack of data and recommendations to guide treatment decisions. Objective: To evaluate the use and efficacy of 4LT in mRCC patients. Methods: The International mRCC Database Consortium (IMDC) dataset was used to identify patients with mRCC treated with 4LT. This is a multicenter, retrospective cohort study. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier curves. Patients were evaluated for overall response. The six prognostic variables included in the IMDC prognostic model were used to stratify patients into favorable-, intermediate- and poor-risk groups. Exploratory analyses were performed examining the elderly (>70 years old) and non-clear cell RCC subgroups. Proportional hazards regression modelling was performed adjusting these covariates by IMDC criteria measured at initiation of 4th line therapy. Results: 7498 patients were treated with first line targeted therapy and out of these 594 (7.9%) received 4LT. Everolimus was the most frequently used 4LT (16.8%). Sorafenib, axitinib, pazopanib, sunitinib and clinical trial drugs were also used in >10% of patients. The OS of patients on any 4LT was 12.8 months, with a PFS of 4.4 months. The overall response rate (ORR) was 13.7%. Favorable-risk patients using IMDC criteria (5%) displayed an OS of 23.1 months, intermediate-risk patients (66%) had an OS of 13.8 months and poor-risk patients (29%) had an OS of 7.8 (p < 0.0001) months. Age >70 years and non-clear cell histology did not impact OS. Our study is limited by its retrospective design. Conclusions: 4LT use appears to have activity in mRCC patients. The IMDC continues to be of prognostic value in the fourth-line setting for OS. This study helps to set a benchmark for response rate and survival for which clinical trials can plan sample size calculations and aim to improve upon.",

keywords = "Checkpoint inhibitors, Fourth line therapy, Metastatic renal cell carcinoma, Targeted therapy",

author = "Igor Stukalin and {Connor Wells}, J. and Anna Fraccon and Felice Pasini and Camillo Porta and Lalani, {Aly Khan A.} and Sandy Srinivas and {Alex Bowman}, I. and James Brugarolas and Lee, {Jae Lyun} and Frede Donskov and Benoit Beuselinck and Aristotelis Bamias and Rini, {Brian I.} and Sim, {Hao Wen} and Neeraj Agarwal and Rha, {Sun Young} and Ravindran Kanesvaran and Choueiri, {Toni K.} and Heng, {Daniel Y.C.}",

year = "2018",

doi = "10.3233/KCA-170020",

language = "English (US)",

volume = "2",

pages = "31--36",

journal = "Kidney Cancer",

issn = "2468-4562",

publisher = "IOS Press BV",

number = "1",

}

TY - JOUR

T1 - Fourth-line therapy in metastatic renal cell carcinoma (mRCC)

T2 - Results from the international mRCC database consortium (IMDC)

AU - Stukalin, Igor

AU - Connor Wells, J.

AU - Fraccon, Anna

AU - Pasini, Felice

AU - Porta, Camillo

AU - Lalani, Aly Khan A.

AU - Srinivas, Sandy

AU - Alex Bowman, I.

AU - Brugarolas, James

AU - Lee, Jae Lyun

AU - Donskov, Frede

AU - Beuselinck, Benoit

AU - Bamias, Aristotelis

AU - Rini, Brian I.

AU - Sim, Hao Wen

AU - Agarwal, Neeraj

AU - Rha, Sun Young

AU - Kanesvaran, Ravindran

AU - Choueiri, Toni K.

AU - Heng, Daniel Y.C.

PY - 2018

Y1 - 2018

N2 - Background: Fourth-line therapy (4LT) in the treatment of metastatic renal cell carcinoma (mRCC) varies significantly due to the lack of data and recommendations to guide treatment decisions. Objective: To evaluate the use and efficacy of 4LT in mRCC patients. Methods: The International mRCC Database Consortium (IMDC) dataset was used to identify patients with mRCC treated with 4LT. This is a multicenter, retrospective cohort study. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier curves. Patients were evaluated for overall response. The six prognostic variables included in the IMDC prognostic model were used to stratify patients into favorable-, intermediate- and poor-risk groups. Exploratory analyses were performed examining the elderly (>70 years old) and non-clear cell RCC subgroups. Proportional hazards regression modelling was performed adjusting these covariates by IMDC criteria measured at initiation of 4th line therapy. Results: 7498 patients were treated with first line targeted therapy and out of these 594 (7.9%) received 4LT. Everolimus was the most frequently used 4LT (16.8%). Sorafenib, axitinib, pazopanib, sunitinib and clinical trial drugs were also used in >10% of patients. The OS of patients on any 4LT was 12.8 months, with a PFS of 4.4 months. The overall response rate (ORR) was 13.7%. Favorable-risk patients using IMDC criteria (5%) displayed an OS of 23.1 months, intermediate-risk patients (66%) had an OS of 13.8 months and poor-risk patients (29%) had an OS of 7.8 (p < 0.0001) months. Age >70 years and non-clear cell histology did not impact OS. Our study is limited by its retrospective design. Conclusions: 4LT use appears to have activity in mRCC patients. The IMDC continues to be of prognostic value in the fourth-line setting for OS. This study helps to set a benchmark for response rate and survival for which clinical trials can plan sample size calculations and aim to improve upon.

AB - Background: Fourth-line therapy (4LT) in the treatment of metastatic renal cell carcinoma (mRCC) varies significantly due to the lack of data and recommendations to guide treatment decisions. Objective: To evaluate the use and efficacy of 4LT in mRCC patients. Methods: The International mRCC Database Consortium (IMDC) dataset was used to identify patients with mRCC treated with 4LT. This is a multicenter, retrospective cohort study. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier curves. Patients were evaluated for overall response. The six prognostic variables included in the IMDC prognostic model were used to stratify patients into favorable-, intermediate- and poor-risk groups. Exploratory analyses were performed examining the elderly (>70 years old) and non-clear cell RCC subgroups. Proportional hazards regression modelling was performed adjusting these covariates by IMDC criteria measured at initiation of 4th line therapy. Results: 7498 patients were treated with first line targeted therapy and out of these 594 (7.9%) received 4LT. Everolimus was the most frequently used 4LT (16.8%). Sorafenib, axitinib, pazopanib, sunitinib and clinical trial drugs were also used in >10% of patients. The OS of patients on any 4LT was 12.8 months, with a PFS of 4.4 months. The overall response rate (ORR) was 13.7%. Favorable-risk patients using IMDC criteria (5%) displayed an OS of 23.1 months, intermediate-risk patients (66%) had an OS of 13.8 months and poor-risk patients (29%) had an OS of 7.8 (p < 0.0001) months. Age >70 years and non-clear cell histology did not impact OS. Our study is limited by its retrospective design. Conclusions: 4LT use appears to have activity in mRCC patients. The IMDC continues to be of prognostic value in the fourth-line setting for OS. This study helps to set a benchmark for response rate and survival for which clinical trials can plan sample size calculations and aim to improve upon.

KW - Checkpoint inhibitors

KW - Fourth line therapy

KW - Metastatic renal cell carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85106144330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106144330&partnerID=8YFLogxK

U2 - 10.3233/KCA-170020

DO - 10.3233/KCA-170020

M3 - Article

AN - SCOPUS:85106144330

SN - 2468-4562

VL - 2

SP - 31

EP - 36

JO - Kidney Cancer

JF - Kidney Cancer

IS - 1

ER -

Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this